These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 8209069)
1. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Mukhopadhyay S; Staddon GE; Eastman C; Palmer M; Davies ER; Carswell F Respir Med; 1994 Mar; 88(3):203-11. PubMed ID: 8209069 [TBL] [Abstract][Full Text] [Related]
2. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients]. Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871 [TBL] [Abstract][Full Text] [Related]
4. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Eisenberg J; Pepe M; Williams-Warren J; Vasiliev M; Montgomery AB; Smith AL; Ramsey BW Chest; 1997 Apr; 111(4):955-62. PubMed ID: 9106575 [TBL] [Abstract][Full Text] [Related]
5. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection. Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995 [TBL] [Abstract][Full Text] [Related]
6. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor. Westerman EM; Boer AH; Touw DJ; Brun PP; Roldaan AC; Frijlink HW; Heijerman HG J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):269-80. PubMed ID: 18759658 [TBL] [Abstract][Full Text] [Related]
7. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. Coates AL; Dinh L; MacNeish CF; Rollin T; Gagnon S; Ho SL; Lands LC J Aerosol Med; 2000; 13(3):169-78. PubMed ID: 11066020 [TBL] [Abstract][Full Text] [Related]
8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. Al-Aloul M; Nazareth D; Walshaw M J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814 [TBL] [Abstract][Full Text] [Related]
9. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
10. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Chua HL; Collis GG; Le Souëf PN Eur Respir J; 1990 Nov; 3(10):1114-6. PubMed ID: 2090472 [TBL] [Abstract][Full Text] [Related]
11. [Use of inhaled tobramycin in patients with cystic fibrosis]. Chermenskiĭ AG; Gembitskaia TE Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251 [TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705 [TBL] [Abstract][Full Text] [Related]
13. Nebulizer delivery of tobramycin to the lower respiratory tract. Weber A; Smith A; Williams-Warren J; Ramsey B; Covert DS Pediatr Pulmonol; 1994 May; 17(5):331-9. PubMed ID: 8058428 [TBL] [Abstract][Full Text] [Related]
14. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. Hasan MA; Lange CF J Aerosol Med; 2007; 20(3):282-93. PubMed ID: 17894535 [TBL] [Abstract][Full Text] [Related]
15. RhDNase I aerosol deposition and related factors in cystic fibrosis. Diot P; Palmer LB; Smaldone A; DeCelie-Germana J; Grimson R; Smaldone GC Am J Respir Crit Care Med; 1997 Nov; 156(5):1662-8. PubMed ID: 9372691 [TBL] [Abstract][Full Text] [Related]
16. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Laube BL; Geller DE; Lin TC; Dalby RN; Diener-West M; Zeitlin PL Respir Care; 2005 Nov; 50(11):1438-44. PubMed ID: 16253150 [TBL] [Abstract][Full Text] [Related]
18. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Ilowite JS; Gorvoy JD; Smaldone GC Am Rev Respir Dis; 1987 Dec; 136(6):1445-9. PubMed ID: 3688646 [TBL] [Abstract][Full Text] [Related]
19. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Geller DE; Rosenfeld M; Waltz DA; Wilmott RW; Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599 [TBL] [Abstract][Full Text] [Related]
20. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Newhouse MT; Hirst PH; Duddu SP; Walter YH; Tarara TE; Clark AR; Weers JG Chest; 2003 Jul; 124(1):360-6. PubMed ID: 12853545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]